Bionano Genomics Announces Participation at the Advances in Genome Biology and Technology (AGBT) General Meeting 2022
- Dr. Alka Chaubey, chief medical officer of Bionano, will present a spotlight session titled “OGM + NGS for Transforming Genome Biology: The Future is Bright!”
- Bionano is a Bronze Sponsor at the conference, and will host customers, KOLs and VIPs from the genomics, cytogenetics, and investment communities at an evening reception
- Conference attendees can experience the Saphyr system and view live demonstrations of Bionano’s NxClinical software at the Bionano suite
- At the women’s networking event, sponsor Bionano will announce a partnership with Ignite Worldwide to advance equity in STEM, and create an opportunity for AGBT attendees to participate and drive donations to the organization
- The company invites social media followers to join in as AGBT participants express their views on OGM and the future of science throughout the conference
AGBT’s General Meeting is an annual conference that brings together industry and academic professionals to discuss new technologies and advances in the field of genome biology. AGBT sessions will take place June 6-9, 2022 in
Details of the presentation:
Session Time:
Title: “OGM + NGS for Transforming Genome Biology: The Future is Bright!”
Presenter:
More details on the conference can be found here.
“Bionano couldn’t be more excited about participating in AGBT. AGBT is where people come together to talk about the most significant advances in genomic technology that we have available. We are excited for
About
Forward-Looking Statements of
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the ability and utility of OGM to complement next generation sequencing (NGS) and provide a more comprehensive analysis of the genome for applications in genetic disease and cancer. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure OGM to achieve useful complementarity with NGS; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Source: Bionano Genomics